Microbiota-Gut-Brain Axis: New Therapeutic Opportunities.
Author: Long-Smith C1, O'Riordan KJ1, Clarke G1,2, Stanton C1,3, Dinan TG1,2, Cryan JF1,4
Affiliation:
1APC Microbiome Ireland, University College Cork, Cork, Ireland; email: J.Cryan@ucc.ie.
2Department of Psychiatry & Neurobehavioral Science, University College Cork, Cork, Ireland.
3Teagasc Food Research Centre, Moorepark, Fermoy, Ireland.
4Department of Anatomy and Neuroscience, University College Cork, Cork, Ireland.
Conference/Journal: Annu Rev Pharmacol Toxicol.
Date published: 2019 Sep 10
Other:
Special Notes: doi: 10.1146/annurev-pharmtox-010919-023628. [Epub ahead of print] , Word Count: 184
The traditional fields of pharmacology and toxicology are beginning to consider the substantial impact our gut microbiota has on host physiology. The microbiota-gut-brain axis is emerging as a particular area of interest and a potential new therapeutic target for effective treatment of central nervous system disorders, in addition to being a potential cause of drug side effects. Microbiota-gut-brain axis signaling can occur via several pathways, including via the immune system, recruitment of host neurochemical signaling, direct enteric nervous system routes and the vagus nerve, and the production of bacterial metabolites. Altered gut microbial profiles have been described in several psychiatric and neurological disorders. Psychobiotics, live biotherapeutics or substances whose beneficial effects on the brain are bacterially mediated, are currently being investigated as direct and/or adjunctive therapies for psychiatric and neurodevelopmental disorders and possibly for neurodegenerative disease, and they may emerge as new therapeutic options in the clinical management of brain disorders. Expected final online publication date for the Annual Review of Pharmacology and Toxicology, Volume 60 is January 6, 2020. Please see http://www.annualreviews.org/page/journal/pubdates for revised estimates.
PMID: 31506009 DOI: 10.1146/annurev-pharmtox-010919-023628
BACK
